Identification	O
of	O
an	O
inducible	B-protein
regulator	I-protein
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	B-cell_type
activation	O
.	O

Resting	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
very	O
low	O
levels	O
of	O
c-Myb	B-protein
protein	I-protein
.	O

During	O
T-cell	O
activation	O
,	O
c-myb	B-DNA
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
that	O
increased	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

In	O
vivo	O
footprinting	O
by	O
ligation-mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein-DNA	B-protein
complex	I-protein
,	O
referred	O
to	O
as	O
CMAT	B-protein
for	O
c-myb	B-protein
in	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Because	O
the	O
binding	B-DNA
site	I-DNA
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	B-protein
EMSA	I-protein
binding	I-protein
complex	I-protein
appeared	O
earlier	O
than	O
the	O
CMAT	B-protein
complex	I-protein
.	O

The	O
NFAT	B-protein
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
than	O
the	O
CMAT	B-protein
protein	I-protein
did	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	B-protein
did	O
not	O
cross-react	O
with	O
the	O
CMAT	B-protein
protein	I-protein
.	O

The	O
appearance	O
of	O
the	O
CMAT	B-protein
binding	I-protein
complex	I-protein
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

The	O
CMAT	B-protein
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGY	NULL
,	NULL
May	NULL
1996	NULL
,	NULL
p.	NULL
2387-2393	NULL
0270-7306/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

16	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Identification	NULL
of	NULL
an	NULL
Inducible	NULL
Regulator	NULL
of	NULL
c-myb	NULL
Expression	NULL
during	NULL
T-Cell	NULL
Activation	NULL
SEE-CHUN	NULL
PHAN	NULL
,	NULL
BRIAN	NULL
FEELEY	NULL
,	NULL
DONALD	NULL
WITHERS	NULL
,	NULL
f	NULL
anp	NULL
LINDA	NULL
M.	NULL
BOXER	NULL
*	NULL
Center	NULL
for	NULL
Molecular	NULL
Biology	NULL
in	NULL
Medicine	NULL
,	NULL
Palo	NULL
Alto	NULL
VAMC	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
California	NULL
94304	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
94305	NULL
Received	NULL
20	NULL
December	NULL
1995/Returned	NULL
for	NULL
modification	NULL
12	NULL
February	NULL
1996/Accepted	NULL
29	NULL
February	NULL
1996	NULL
Resting	NULL
T	NULL
cells	NULL
express	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
c-Myb	NULL
protein	NULL
.	NULL

During	NULL
T-cell	NULL
activation	NULL
,	NULL
c-myb	NULL
expression	NULL
is	NULL
induced	NULL
and	NULL
much	NULL
of	NULL
the	NULL
increase	NULL
in	NULL
expression	NULL
occurs	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

We	NULL
identified	NULL
a	NULL
region	NULL
of	NULL
the	NULL
c-myb	NULL
5	NULL
'	NULL
flanking	NULL
sequence	NULL
that	NULL
increased	NULL
c-myb	NULL
expression	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
by	NULL
ligation-mediated	NULL
PCR	NULL
was	NULL
performed	NULL
to	NULL
correlate	NULL
in	NULL
vivo	NULL
protein	NULL
binding	NULL
with	NULL
functional	NULL
activity	NULL
.	NULL

A	NULL
protein	NULL
footprint	NULL
was	NULL
visible	NULL
over	NULL
this	NULL
region	NULL
of	NULL
the	NULL
c-myb	NULL
5	NULL
'	NULL
flanking	NULL
sequence	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
unactivated	NULL
T	NULL
cells	NULL
.	NULL

An	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
an	NULL
oligonucleotide	NULL
of	NULL
this	NULL
binding	NULL
site	NULL
demonstrated	NULL
a	NULL
new	NULL
protein-DNA	NULL
complex	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
CMAT	NULL
for	NULL
c-myb	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
this	NULL
complex	NULL
was	NULL
not	NULL
present	NULL
in	NULL
unactivated	NULL
T	NULL
cells	NULL
.	NULL

Because	NULL
the	NULL
binding	NULL
site	NULL
showed	NULL
some	NULL
sequence	NULL
similarity	NULL
with	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
binding	NULL
site	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
kinetics	NULL
of	NULL
induction	NULL
of	NULL
the	NULL
two	NULL
binding	NULL
complexes	NULL
and	NULL
the	NULL
molecular	NULL
masses	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
kinetics	NULL
of	NULL
induction	NULL
showed	NULL
that	NULL
the	NULL
NFAT	NULL
EMSA	NULL
binding	NULL
complex	NULL
appeared	NULL
earlier	NULL
than	NULL
the	NULL
CMAT	NULL
complex	NULL
.	NULL

The	NULL
NFAT	NULL
protein	NULL
migrated	NULL
more	NULL
slowly	NULL
in	NULL
a	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
than	NULL
the	NULL
CMAT	NULL
protein	NULL
did	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
an	NULL
antibody	NULL
against	NULL
NFAT	NULL
did	NULL
not	NULL
cross-react	NULL
with	NULL
the	NULL
CMAT	NULL
protein	NULL
.	NULL

The	NULL
appearance	NULL
of	NULL
the	NULL
CMAT	NULL
binding	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
rapamycin	NULL
.	NULL

The	NULL
CMAT	NULL
protein	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
novel	NULL
inducible	NULL
protein	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
c-myb	NULL
expression	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

Interaction	NULL
of	NULL
antigen	NULL
with	NULL
the	NULL
antigen	NULL
receptor	NULL
of	NULL
T	NULL
lymphocytes	NULL
initiates	NULL
a	NULL
series	NULL
of	NULL
changes	NULL
resulting	NULL
in	NULL
cell	NULL
division	NULL
and	NULL
immunologic	NULL
function	NULL
.	NULL

The	NULL
antigen	NULL
receptor	NULL
rapidly	NULL
induces	NULL
the	NULL
production	NULL
of	NULL
cytokines	NULL
that	NULL
control	NULL
cell	NULL
proliferation	NULL
,	NULL
cell	NULL
fate	NULL
decisions	NULL
,	NULL
and	NULL
the	NULL
differentiation	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
granulocytes	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
other	NULL
cell	NULL
types	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
3	NULL
,	NULL
13	NULL
,	NULL
30	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
genes	NULL
are	NULL
activated	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
including	NULL
the	NULL
proto-oncogenes	NULL
c-myc	NULL
and	NULL
c-myh	NULL
(	NULL
17	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
products	NULL
of	NULL
these	NULL
genes	NULL
provide	NULL
a	NULL
link	NULL
with	NULL
surface	NULL
receptor-mediated	NULL
activation	NULL
events	NULL
and	NULL
prepare	NULL
the	NULL
cell	NULL
for	NULL
subsequent	NULL
DNA	NULL
replication	NULL
and	NULL
proliferation	NULL
.	NULL

The	NULL
interleukin-2	NULL
gene	NULL
is	NULL
active	NULL
only	NULL
in	NULL
T	NULL
cells	NULL
that	NULL
have	NULL
been	NULL
stimulated	NULL
through	NULL
the	NULL
antigen	NULL
receptor	NULL
,	NULL
and	NULL
it	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
T-cell	NULL
proliferation	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
transcription	NULL
factor	NULL
,	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
(	NULL
9	NULL
,	NULL
35	NULL
,	NULL
40	NULL
)	NULL
.	NULL

The	NULL
NFAT	NULL
complex	NULL
is	NULL
found	NULL
in	NULL
nuclei	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
it	NULL
binds	NULL
to	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
and	NULL
transmits	NULL
signals	NULL
initiated	NULL
at	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

NFAT	NULL
is	NULL
assembled	NULL
from	NULL
a	NULL
preexisting	NULL
,	NULL
T-cell-restricted	NULL
cytoplasmic	NULL
factor	NULL
and	NULL
an	NULL
inducible	NULL
ubiquitous	NULL
nuclear	NULL
component	NULL
consisting	NULL
of	NULL
API	NULL
factors	NULL
within	NULL
30	NULL
min	NULL
after	NULL
activation	NULL
of	NULL
the	NULL
antigen	NULL
receptor	NULL
(	NULL
10	NULL
,	NULL
29	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
component	NULL
(	NULL
NFAT	NULL
)	NULL
is	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
response	NULL
to	NULL
calcium	NULL
signaling	NULL
,	NULL
and	NULL
this	NULL
process	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

c-Myb	NULL
is	NULL
a	NULL
sequence-specific	NULL
DNA-binding	NULL
protein	NULL
with	NULL
the	NULL
ability	NULL
to	NULL
transactivate	NULL
promoters	NULL
with	NULL
the	NULL
specific	NULL
consensus	NULL
sequence	NULL
PyAACG/TG	NULL
.	NULL

The	NULL
c-myb	NULL
gene	NULL
product	NULL
is	NULL
a	NULL
highly	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Division	NULL
of	NULL
Hematology	NULL
,	NULL
S-161	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305-5112	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
415	NULL
)	NULL
493-5000	NULL
,	NULL
ext	NULL
.	NULL

63126	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
415	NULL
)	NULL
858-3982	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
hf.Imb	NULL
@	NULL
forsythe.stanford.edu	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
The	NULL
Biomembrane	NULL
Institute	NULL
,	NULL
University	NULL
of	NULL
Wash-ington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98119	NULL
.	NULL

2387	NULL
conserved	NULL
75-	NULL
to	NULL
83-kDa	NULL
phosphoprotein	NULL
which	NULL
is	NULL
predominantly	NULL
expressed	NULL
in	NULL
hematopoietic	NULL
tissues	NULL
and	NULL
localized	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
18	NULL
,	NULL
19	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Reduction	NULL
of	NULL
c-myb	NULL
expression	NULL
results	NULL
in	NULL
a	NULL
block	NULL
to	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
homozygous	NULL
c-myb	NULL
mutant	NULL
mice	NULL
demonstrate	NULL
greatly	NULL
impaired	NULL
fetal	NULL
hepatic	NULL
hematopoiesis	NULL
.	NULL

The	NULL
c-myb	NULL
gene	NULL
product	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

c-myb	NULL
mRNA	NULL
levels	NULL
vary	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
of	NULL
normal	NULL
T	NULL
lymphocytes	NULL
and	NULL
reach	NULL
a	NULL
peak	NULL
in	NULL
S	NULL
phase	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Resting	NULL
T	NULL
cells	NULL
express	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
c-Myb	NULL
.	NULL

During	NULL
T-cell	NULL
activation	NULL
,	NULL
levels	NULL
of	NULL
c-myb	NULL
mRNA	NULL
increase	NULL
manyfold	NULL
(	NULL
8	NULL
,	NULL
31	NULL
,	NULL
36-38	NULL
)	NULL
.	NULL

An-tisense	NULL
experiments	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
c-myb	NULL
gene	NULL
product	NULL
is	NULL
required	NULL
for	NULL
T	NULL
cells	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Reduction	NULL
of	NULL
c-Myb	NULL
levels	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
T	NULL
lymphocyte	NULL
activation	NULL
or	NULL
early	NULL
molecular	NULL
events	NULL
,	NULL
but	NULL
it	NULL
does	NULL
block	NULL
the	NULL
T	NULL
cells	NULL
in	NULL
late	NULL
G	NULL
,	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
control	NULL
of	NULL
c-myb	NULL
expression	NULL
has	NULL
been	NULL
examined	NULL
in	NULL
several	NULL
studies	NULL
(	NULL
14	NULL
,	NULL
16	NULL
,	NULL
22	NULL
,	NULL
24	NULL
,	NULL
26	NULL
,	NULL
27	NULL
)	NULL
,	NULL
but	NULL
it	NULL
is	NULL
not	NULL
known	NULL
how	NULL
e-myb	NULL
expression	NULL
is	NULL
controlled	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
have	NULL
identified	NULL
a	NULL
region	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
that	NULL
mediates	NULL
an	NULL
increase	NULL
in	NULL
c-myb	NULL
expression	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

An	NULL
inducible	NULL
protein	NULL
,	NULL
CMAT	NULL
(	NULL
c-myb	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
binds	NULL
to	NULL
this	NULL
sequence	NULL
.	NULL

The	NULL
CMAT	NULL
binding	NULL
site	NULL
shows	NULL
some	NULL
sequence	NULL
similarities	NULL
with	NULL
the	NULL
NFAT	NULL
binding	NULL
site	NULL
,	NULL
but	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
CMAT	NULL
binding	NULL
activity	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
NFAT	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
CMAT	NULL
complex	NULL
is	NULL
present	NULL
only	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
Jurkat	NULL
TagC	NULL
cell	NULL
line	NULL
(	NULL
29	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
G.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
50	NULL
U	NULL
of	NULL
penicillin	NULL
G	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
50	NULL
ug	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
.	NULL

For	NULL
activation	NULL
,	NULL
20	NULL
ng	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
1	NULL
wM	NULL
ionomycin	NULL
were	NULL
added	NULL
.	NULL

The	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
anisomycin	NULL
was	NULL
added	NULL
at	NULL
100	NULL
M	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
activation	NULL
in	NULL
the	NULL
gel	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
4	NULL
.	NULL

Cyclosporin	NULL
A	NULL
or	NULL
rapamycin	NULL
at	NULL
the	NULL
concentrations	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
was	NULL
added	NULL
5	NULL
to	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
activation	NULL
where	NULL
indicated	NULL
in	NULL
2388	NULL
PHAN	NULL
ET	NULL
AL	NULL
.	NULL

the	NULL
figure	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
or	NULL
at	NULL
8	NULL
h	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Peripheral	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Monocytes	NULL
were	NULL
removed	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
flasks	NULL
,	NULL
and	NULL
B	NULL
lymphocytes	NULL
were	NULL
depleted	NULL
by	NULL
nylon	NULL
wool	NULL
columns	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
further	NULL
purified	NULL
by	NULL
discontinuous	NULL
Percoll	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Purity	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
as	NULL
assessed	NULL
by	NULL
flow	NULL
cytom-etry	NULL
.	NULL

Activation	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Construction	NULL
of	NULL
reporter	NULL
plasmids	NULL
.	NULL

The	NULL
fragment	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
vector	NULL
was	NULL
derived	NULL
from	NULL
pSV232AL-AA5	NULL
'	NULL
(	NULL
obtained	NULL
from	NULL
D.	NULL
Helinski	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
pUC18	NULL
and	NULL
subsequently	NULL
recut	NULL
as	NULL
a	NULL
HindIII-KprI	NULL
fragment	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
multiple	NULL
cloning	NULL
site	NULL
of	NULL
Bluescript	NULL
II	NULL
KS+	NULL
.	NULL

The	NULL
2.3-kb	NULL
EcoRI-EcoRI	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
of	NULL
human	NULL
emyb	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
R.	NULL
Dalla-Favera	NULL
,	NULL
Columbia	NULL
University	NULL
)	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
5°	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
in	NULL
Bluescript	NULL
.	NULL

To	NULL
remove	NULL
a	NULL
confounding	NULL
ATG	NULL
site	NULL
,	NULL
the	NULL
HindIII-Neol	NULL
fragment	NULL
was	NULL
removed	NULL
,	NULL
HindIII	NULL
linkers	NULL
were	NULL
added	NULL
,	NULL
and	NULL
the	NULL
plasmid	NULL
was	NULL
religated	NULL
.	NULL

The	NULL
deletion	NULL
constructs	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
were	NULL
made	NULL
by	NULL
PCR	NULL
from	NULL
this	NULL
original	NULL
construct	NULL
.	NULL

All	NULL
numbers	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
CMAT	NULL
binding	NULL
site	NULL
was	NULL
achieved	NULL
by	NULL
a	NULL
technique	NULL
previously	NULL
described	NULL
by	NULL
Higuchi	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Mutants	NULL
were	NULL
screened	NULL
by	NULL
restriction	NULL
enzyme	NULL
analysis	NULL
and	NULL
subsequently	NULL
sequenced	NULL
with	NULL
a	NULL
Fmol	NULL
sequencing	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
or	NULL
a	NULL
Sequenase	NULL
kit	NULL
(	NULL
U.S.	NULL
Biochemicals	NULL
)	NULL
.	NULL

Compressions	NULL
were	NULL
resolved	NULL
with	NULL
dITP	NULL
or	NULL
deaza-dGTP	NULL
.	NULL

The	NULL
oligonucleotide	NULL
sequence	NULL
used	NULL
for	NULL
the	NULL
PCR	NULL
primer	NULL
(	NULL
with	NULL
mutated	NULL
bases	NULL
shown	NULL
in	NULL
boldface	NULL
type	NULL
)	NULL
was	NULL
GGTGGCGGCCGAAGAAGAATTAAAA	NULL
AAAA	NULL
.	NULL

Transfections	NULL
and	NULL
luciferase	NULL
assays	NULL
.	NULL

Transfections	NULL
were	NULL
performed	NULL
on	NULL
cells	NULL
in	NULL
log	NULL
phase	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
unsupplemented	NULL
RPMI	NULL
1640	NULL
medium	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
per	NULL
ml	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
DNA	NULL
.	NULL

Electroporations	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
at	NULL
250	NULL
mV	NULL
and	NULL
960	NULL
pF	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
again	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
24	NULL
ml	NULL
of	NULL
supplemented	NULL
RPMI	NULL
1640	NULL
medium	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
either	NULL
unactivated	NULL
or	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
for	NULL
10	NULL
h.	NULL
Cell	NULL
lysis	NULL
and	NULL
luciferase	NULL
assays	NULL
were	NULL
conducted	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
and	NULL
with	NULL
reagents	NULL
supplied	NULL
with	NULL
Promega	NULL
's	NULL
luciferase	NULL
assay	NULL
system	NULL
.	NULL

Luciferase	NULL
measurements	NULL
were	NULL
performed	NULL
on	NULL
a	NULL
model	NULL
LKB	NULL
1251	NULL
luminometer	NULL
.	NULL

A	NULL
plasmid	NULL
expressing	NULL
B-galac-tosidase	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
of	NULL
the	NULL
transfection	NULL
efficiency	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
three	NULL
times	NULL
in	NULL
duplicate	NULL
with	NULL
at	NULL
least	NULL
three	NULL
different	NULL
DNA	NULL
preparations	NULL
.	NULL

The	NULL
average	NULL
values	NULL
with	NULL
the	NULL
standard	NULL
deviations	NULL
were	NULL
plotted	NULL
.	NULL

EMSA	NULL
.	NULL

The	NULL
following	NULL
oligonucleotides	NULL
were	NULL
used	NULL
for	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
:	NULL
CMAT	NULL
AAGAACAAGCAAAAAAAACCCTAGC	NULL
TICITCIICCTTIIIIIIGGGATCG	NULL
NFAT	NULL
TCIAAGCAGCAAAAACTGTIICATG	NULL
AGATTCCTCCTTIIIGACAAAGTAT	NULL
Mutated	NULL
CMAT	NULL
-	NULL
AAGAAGAATTAAAAAAAACCCTAGC	NULL
TTCTITCTIITAATIIIIIIIGGGATCG	NULL
The	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
5	NULL
'	NULL
overhangs	NULL
and	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
«	NULL
-P	NULL
]	NULL
dCTP	NULL
and	NULL
Klenow	NULL
fragment	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
mixture	NULL
contained	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
30	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
6	NULL
mg	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
,	NULL
0.5	NULL
ng	NULL
(	NULL
10*	NULL
cpm	NULL
)	NULL
of	NULL
end-labeled	NULL
DNA	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
and	NULL
5	NULL
to	NULL
10	NULL
pg	NULL
of	NULL
protein	NULL
from	NULL
crude	NULL
nuclear	NULL
extract	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
was	NULL
conducted	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
60	NULL
min	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
loaded	NULL
onto	NULL
a	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA-5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
at	NULL
30	NULL
mA	NULL
at	NULL
4°C	NULL
.	NULL

For	NULL
the	NULL
competition	NULL
studies	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
and	NULL
C	NULL
,	NULL
the	NULL
indicated	NULL
molar	NULL
excesses	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
were	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
.	NULL

For	NULL
the	NULL
supershifts	NULL
,	NULL
the	NULL
binding	NULL
reaction	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
with	NULL
incubation	NULL
for	NULL
60	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Antibody	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cytosolic	NULL
and	NULL
preexisting	NULL
NFAT	NULL
(	NULL
NFAT	NULL
,	NULL
and	NULL
NFAT	NULL
,	NULL
respectively	NULL
)	NULL
antibodies	NULL
(	NULL
28	NULL
)	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
G.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
)	NULL
.	NULL

Antibodies	NULL
against	NULL
Fos	NULL
,	NULL
Jun	NULL
,	NULL
and	NULL
Ets	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

UV	NULL
cross-linking	NULL
and	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

An	NULL
EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
wet	NULL
gel	NULL
was	NULL
exposed	NULL
to	NULL
film	NULL
to	NULL
locate	NULL
the	NULL
complexes	NULL
.	NULL

UV	NULL
cross-linking	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
)	NULL
on	NULL
a	NULL
short-wave	NULL
UV	NULL
light	NULL
box	NULL
at	NULL
4°C	NULL
for	NULL
90	NULL
min	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
the	NULL
gel	NULL
containing	NULL
the	NULL
complexes	NULL
were	NULL
cut	NULL
out	NULL
,	NULL
and	NULL
the	NULL
complexes	NULL
were	NULL
eluted	NULL
at	NULL
room	NULL
temperature	NULL
overnight	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-0.1	NULL
mM	NULL
EDTA-5	NULL
mM	NULL
dithiothreitol-150	NULL
mM	NULL
NaCl-O0.1	NULL
mg	NULL
of	NULL
BSA	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
eluted	NULL
protein	NULL
was	NULL
precipitated	NULL
with	NULL
4	NULL
volumes	NULL
of	NULL
acetone	NULL
,	NULL
washed	NULL
with	NULL
ethanol	NULL
,	NULL
and	NULL
air	NULL
dried	NULL
.	NULL

After	NULL
resuspension	NULL
in	NULL
Laemmli	NULL
loading	NULL
buffer	NULL
,	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
was	NULL
performed	NULL
and	NULL
the	NULL
labeled	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Preparation	NULL
and	NULL
analysis	NULL
of	NULL
RNA	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
guanidinium	NULL
thiocyanate	NULL
method	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
RNA	NULL
per	NULL
sample	NULL
was	NULL
separated	NULL
on	NULL
1.2	NULL
%	NULL
agarose-formaldehyde	NULL
gels	NULL
.	NULL

The	NULL
RNA	NULL
was	NULL
blotted	NULL
onto	NULL
Hy-bond-N	NULL
filters	NULL
(	NULL
Amersham	NULL
)	NULL
and	NULL
processed	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
in	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

structions	NULL
.	NULL

The	NULL
e-myb	NULL
probe	NULL
was	NULL
an	NULL
EcoRI	NULL
fragment	NULL
of	NULL
human	NULL
e-myb	NULL
cDNA	NULL
(	NULL
20	NULL
)	NULL
labeled	NULL
by	NULL
random	NULL
priming	NULL
.	NULL

Human	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
cDNA	NULL
cloned	NULL
into	NULL
the	NULL
Psfl	NULL
site	NULL
of	NULL
pBR322	NULL
(	NULL
39	NULL
)	NULL
was	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
for	NULL
a	NULL
housekeeping	NULL
mRNA	NULL
.	NULL

In	NULL
vitro	NULL
methylation	NULL
interference	NULL
.	NULL

5°	NULL
end-labeled	NULL
oligonucleotide	NULL
(	NULL
labeled	NULL
with	NULL
T4	NULL
kinase	NULL
)	NULL
was	NULL
methylated	NULL
with	NULL
0.5	NULL
%	NULL
dimethyl	NULL
sulfate	NULL
for	NULL
2	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

This	NULL
probe	NULL
was	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
wet	NULL
gel	NULL
was	NULL
exposed	NULL
to	NULL
locate	NULL
the	NULL
complexes	NULL
,	NULL
and	NULL
both	NULL
the	NULL
bound	NULL
and	NULL
free	NULL
probes	NULL
were	NULL
excised	NULL
and	NULL
transferred	NULL
to	NULL
DEAE	NULL
membranes	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
eluted	NULL
and	NULL
cleaved	NULL
with	NULL
piperidine	NULL
,	NULL
and	NULL
equal	NULL
counts	NULL
of	NULL
bound	NULL
and	NULL
free	NULL
samples	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
15	NULL
%	NULL
acrylamide	NULL
sequencing	NULL
gel	NULL
.	NULL

In	NULL
vivo	NULL
dimethyl	NULL
sulfate	NULL
treatment	NULL
and	NULL
DNA	NULL
isolation	NULL
.	NULL

DNA	NULL
isolation	NULL
after	NULL
dimethyl	NULL
sulfate	NULL
treatment	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Cleay-age	NULL
with	NULL
piperidine	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
Maxam-Gilbert	NULL
procedure	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Ligation-mediated	NULL
PCR	NULL
.	NULL

Chemically	NULL
modified	NULL
and	NULL
cleaved	NULL
DNA	NULL
was	NULL
subjected	NULL
to	NULL
amplification	NULL
by	NULL
ligation-mediated	NULL
PCR	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Mueller	NULL
and	NULL
Wold	NULL
(	NULL
25	NULL
)	NULL
,	NULL
Pfeifer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
,	NULL
and	NULL
Garrity	NULL
and	NULL
Wold	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Sequenase	NULL
was	NULL
used	NULL
for	NULL
first-strand	NULL
synthesis	NULL
,	NULL
and	NULL
Teg	NULL
DNA	NULL
polymerase	NULL
was	NULL
used	NULL
for	NULL
PCR	NULL
.	NULL

Conditions	NULL
used	NULL
for	NULL
amplification	NULL
were	NULL
95°C	NULL
for	NULL
2	NULL
min	NULL
,	NULL
61°C	NULL
for	NULL
2	NULL
min	NULL
,	NULL
and	NULL
76°C	NULL
for	NULL
3	NULL
min	NULL
.	NULL

After	NULL
20	NULL
to	NULL
22	NULL
cycles	NULL
of	NULL
PCR	NULL
,	NULL
samples	NULL
were	NULL
hybridized	NULL
with	NULL
end-labeled	NULL
primers	NULL
(	NULL
primer	NULL
3	NULL
of	NULL
each	NULL
primer	NULL
set	NULL
)	NULL
and	NULL
amplified	NULL
by	NULL
one	NULL
more	NULL
cycle	NULL
of	NULL
PCR	NULL
.	NULL

The	NULL
reaction	NULL
mixtures	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
denaturing	NULL
gel	NULL
.	NULL

The	NULL
common	NULL
linkers	NULL
used	NULL
were	NULL
GCGGTGACCCGGGAGATCTGAATTC	NULL
and	NULL
GAATTCAGATC	NULL
.	NULL

The	NULL
primers	NULL
for	NULL
the	NULL
coding	NULL
strand	NULL
were	NULL
:	NULL
TGGAGACG	NULL
GGGAAATTAGGAGTTGG	NULL
,	NULL
GTTGGAGGAGTAGGGGATGTGAGC	NULL
,	NULL
and	NULL
GTTGGAGGAGTAGGGGATGTGAGCATATG	NULL
.	NULL

RESULTS	NULL
Identification	NULL
of	NULL
a	NULL
site	NULL
that	NULL
mediates	NULL
activation	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
during	NULL
Jurkat	NULL
T-cell	NULL
activation	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
contribution	NULL
of	NULL
transcriptional	NULL
initiation	NULL
to	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
c-myb	NULL
during	NULL
Jurkat	NULL
T-cell	NULL
activation	NULL
,	NULL
promoter-re-porter	NULL
constructs	NULL
were	NULL
made	NULL
with	NULL
the	NULL
cmyh	NULL
5°	NULL
flanking	NULL
sequence	NULL
and	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

We	NULL
identified	NULL
a	NULL
region	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
that	NULL
mediated	NULL
an	NULL
increase	NULL
in	NULL
promoter	NULL
activity	NULL
during	NULL
Jurkat	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
location	NULL
of	NULL
this	NULL
region	NULL
in	NULL
the	NULL
c-myb	NULL
promoter	NULL
is	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

Inclusion	NULL
of	NULL
a	NULL
region	NULL
between	NULL
positions	NULL
-784	NULL
and	NULL
-758	NULL
resulted	NULL
in	NULL
a	NULL
9.2-fold	NULL
increase	NULL
in	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
and	NULL
only	NULL
a	NULL
1.4-fold	NULL
increase	NULL
in	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Further	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
characterize	NULL
this	NULL
regulatory	NULL
element	NULL
.	NULL

A	NULL
specific	NULL
complex	NULL
is	NULL
formed	NULL
with	NULL
the	NULL
-784-to	NULL
--	NULL
758	NULL
region	NULL
in	NULL
EMSA	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
unactivated	NULL
and	NULL
activated	NULL
Jurkat	NULL
or	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
used	NULL
in	NULL
EMSA	NULL
with	NULL
the	NULL
-784-to	NULL
--	NULL
758	NULL
region	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
both	NULL
Jurkat	NULL
and	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
single	NULL
complex	NULL
of	NULL
retarded	NULL
mobility	NULL
was	NULL
observed	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
unactivated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
same	NULL
complex	NULL
was	NULL
observed	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
in	NULL
addition	NULL
,	NULL
a	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
was	NULL
also	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

EMSA	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
several	NULL
other	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
did	NULL
not	NULL
reveal	NULL
any	NULL
complex	NULL
with	NULL
the	NULL
migration	NULL
pattern	NULL
of	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
activated-T	NULL
-cell	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
refer	NULL
to	NULL
this	NULL
complex	NULL
as	NULL
CMAT	NULL
.	NULL

The	NULL
guanine	NULL
residues	NULL
at	NULL
positions	NULL
-779	NULL
and	NULL
-778	NULL
are	NULL
required	NULL
for	NULL
binding	NULL
,	NULL
as	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
.	NULL

The	NULL
mutated	NULL
oligonucleotide	NULL
did	NULL
not	NULL
compete	NULL
against	NULL
the	NULL
CMAT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
the	NULL
CMAT	NULL
complex	NULL
was	NULL
not	NULL
formed	NULL
when	NULL
the	NULL
mutated	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
for	NULL
EMSA	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
methylation	NULL
interference	NULL
confirmed	NULL
that	NULL
the	NULL
guanines	NULL
at	NULL
-779	NULL
and	NULL
-778	NULL
were	NULL
required	NULL
for	NULL
protein	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
methylation	NULL
of	NULL
the	NULL
guanine	NULL
residue	NULL
at	NULL
-782	NULL
interfered	NULL
with	NULL
protein	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Formation	NULL
of	NULL
the	NULL
constitutive	NULL
complex	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
methylation	NULL
of	NULL
any	NULL
of	NULL
these	NULL
guanine	NULL
residues	NULL
.	NULL

We	NULL
did	NULL
observe	NULL
a	NULL
consistent	NULL
decrease	NULL
in	NULL
intensity	NULL
of	NULL
the	NULL
guanine	NULL
at	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
A	NULL
Luciferase	NULL
Activity	NULL
-784	NULL
+758	NULL
Mut	NULL
-784	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Results	NULL
of	NULL
transient	NULL
transfection	NULL
experiments	NULL
with	NULL
the	NULL
c-myb	NULL
5	NULL
'	NULL
flanking	NULL
sequence	NULL
during	NULL
Jurkat	NULL
T-cell	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Diagram	NULL
of	NULL
c-myb	NULL
5°	NULL
flanking	NULL
sequence	NULL
and	NULL
first	NULL
exon	NULL
.	NULL

The	NULL
arrow	NULL
marks	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
,	NULL
and	NULL
the	NULL
X	NULL
across	NULL
the	NULL
line	NULL
marks	NULL
the	NULL
location	NULL
of	NULL
the	NULL
CMAT	NULL
site	NULL
.	NULL

The	NULL
transcription	NULL
initiation	NULL
site	NULL
is	NULL
200	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
ATG	NULL
codon	NULL
.	NULL

Restriction	NULL
sites	NULL
:	NULL
RI	NULL
,	NULL
EcoRI	NULL
;	NULL
X	NULL
,	NULL
Xbal	NULL
;	NULL
P	NULL
,	NULL
Psfl	NULL
;	NULL
B	NULL
,	NULL
BamHI	NULL
;	NULL
S	NULL
,	NULL
Sacl	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transient	NULL
transfection	NULL
analysis	NULL
of	NULL
the	NULL
c-myb	NULL
promoter-luciferase	NULL
constructs	NULL
spanning	NULL
the	NULL
CMAT	NULL
site	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
relative	NULL
to	NULL
the	NULL
luciferase	NULL
activity	NULL
of	NULL
a	NULL
promoterless	NULL
construct	NULL
.	NULL

The	NULL
CMAT	NULL
site	NULL
is	NULL
at	NULL
-782	NULL
.	NULL

Mut-784	NULL
is	NULL
the	NULL
-784	NULL
construct	NULL
with	NULL
the	NULL
guanines	NULL
at	NULL
positions	NULL
-779	NULL
and	NULL
-778	NULL
changed	NULL
to	NULL
thymidines	NULL
.	NULL

All	NULL
numbers	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

unact	NULL
.	NULL

,	NULL
unactivated	NULL
;	NULL
act	NULL
.	NULL

,	NULL
activated	NULL
.	NULL

-694	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
noncoding	NULL
strand	NULL
.	NULL

None	NULL
of	NULL
the	NULL
guanines	NULL
on	NULL
the	NULL
noncoding	NULL
strand	NULL
showed	NULL
any	NULL
decrease	NULL
in	NULL
intensity	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
not	NULL
defined	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
constitutive	NULL
complex	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
sequences	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
CMAT	NULL
oligonucleotide	NULL
are	NULL
able	NULL
to	NULL
compete	NULL
for	NULL
INDUCIBLE	NULL
REGULATOR	NULL
OF	NULL
cmyb	NULL
EXPRESSION	NULL
2389	NULL
binding	NULL
of	NULL
the	NULL
constitutive	NULL
complex	NULL
in	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
CMAT	NULL
binding	NULL
by	NULL
EMSA	NULL
correlated	NULL
with	NULL
the	NULL
function	NULL
of	NULL
the	NULL
CMAT	NULL
site	NULL
,	NULL
the	NULL
two	NULL
guanine	NULL
residues	NULL
at	NULL
-779	NULL
and	NULL
-778	NULL
were	NULL
mutated	NULL
in	NULL
the	NULL
ec-myb	NULL
promoter-re-porter	NULL
construct	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
that	NULL
this	NULL
mutation	NULL
abolished	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
cnyb	NULL
promoter	NULL
activity	NULL
level	NULL
during	NULL
Jurkat	NULL
T-cell	NULL
activation	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
CMAT	NULL
and	NULL
NFAT	NULL
complexes	NULL
.	NULL

Because	NULL
the	NULL
CMAT	NULL
sequence	NULL
showed	NULL
some	NULL
similarity	NULL
to	NULL
that	NULL
of	NULL
the	NULL
NFAT	NULL
site	NULL
and	NULL
the	NULL
NFAT	NULL
complex	NULL
is	NULL
also	NULL
present	NULL
only	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
investigate	NULL
whether	NULL
the	NULL
same	NULL
proteins	NULL
were	NULL
present	NULL
in	NULL
both	NULL
complexes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
the	NULL
NFAT	NULL
complex	NULL
migrated	NULL
more	NULL
slowly	NULL
than	NULL
the	NULL
CMAT	NULL
complex	NULL
in	NULL
EMSA	NULL
(	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
CMAT	NULL
complex	NULL
competed	NULL
weakly	NULL
for	NULL
binding	NULL
with	NULL
the	NULL
NFAT	NULL
complex	NULL
at	NULL
a	NULL
75-fold	NULL
molar	NULL
excess	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
the	NULL
NFAT	NULL
complex	NULL
also	NULL
demonstrated	NULL
weak	NULL
competition	NULL
with	NULL
the	NULL
CMAT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

At	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
self	NULL
competitor	NULL
,	NULL
the	NULL
complex	NULL
disappeared	NULL
completely	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Supershift	NULL
EMSA	NULL
were	NULL
performed	NULL
with	NULL
antibodies	NULL
against	NULL
NFAT	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
CMAT	NULL
complex	NULL
contained	NULL
the	NULL
NFAT	NULL
protein	NULL
.	NULL

Antibodies	NULL
against	NULL
both	NULL
NFAT	NULL
,	NULL
and	NULL
NFAT	NULL
,	NULL
produced	NULL
supershifted	NULL
bands	NULL
with	NULL
the	NULL
NFAT	NULL
probe	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

No	NULL
supershifted	NULL
band	NULL
was	NULL
visible	NULL
with	NULL
the	NULL
antibody	NULL
against	NULL
either	NULL
NFAT	NULL
,	NULL
or	NULL
NFAT	NULL
,	NULL
with	NULL
the	NULL
CMAT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

No	NULL
supershifted	NULL
complex	NULL
was	NULL
visible	NULL
with	NULL
antibodies	NULL
against	NULL
Fos	NULL
,	NULL
Jun	NULL
,	NULL
or	NULL
Ets	NULL
with	NULL
the	NULL
CMAT	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
the	NULL
CMAT	NULL
protein	NULL
,	NULL
UV	NULL
cross-linking	NULL
of	NULL
the	NULL
EMSA	NULL
complex	NULL
followed	NULL
by	NULL
denaturing	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
was	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

After	NULL
correction	NULL
for	NULL
the	NULL
bound	NULL
oligonucleotide	NULL
,	NULL
a	NULL
molecular	NULL
A	NULL
B	NULL
C	NULL
Competitor	NULL
:	NULL
O	NULL
0	NULL
Mut	NULL
0	NULL
Coding	NULL
Competitor	NULL
:	NULL
0	NULL
0	NULL
M	NULL
N	NULL
O0	NULL
0	NULL
N	NULL
M	NULL
Activated	NULL
:	NULL
-	NULL
+	NULL
+	NULL
+	NULL
1	NULL
2	NULL
3	NULL
,	NULL
Activated	NULL
:	NULL
-	NULL
O+	NULL
O+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
+	NULL
lam	NULL
6	NULL
<	NULL
fam	NULL
ham	NULL
7x	NULL
,	NULL
Noncoding	NULL
3	NULL
w	NULL
a	NULL
o	NULL
1	NULL
2	NULL
3	NULL
|	NULL
NFAT-	NULL
-	NULL
Act	NULL
Activated	NULL
-	NULL
A	NULL
i	NULL
t	NULL
‘	NULL
HH	NULL
'	NULL
’	NULL
H	NULL
,	NULL
'	NULL
Activated	NULL
I	NULL
|	NULL
R	NULL
:	NULL
Constitutive	NULL
,	NULL
-778	NULL
h	NULL
-	NULL
Constitutive	NULL
e	NULL
G\	NULL
|	NULL
,	NULL
'	NULL
i	NULL
Cif	NULL
Heke	NULL
~	NULL
I0	NULL
A	NULL
tj	NULL
H	NULL
§	NULL
]	NULL
b	NULL
.	NULL

A	NULL
f	NULL
_	NULL
H	NULL
e	NULL
G	NULL
**	NULL
H	NULL
H	NULL
H	NULL
H	NULL
A	NULL
A	NULL
__	NULL
ams	NULL
E	NULL
kaal	NULL
a	NULL
w	NULL
1	NULL
20	NULL
3	NULL
4	NULL
``	NULL
785	NULL
Probe	NULL
:	NULL
--	NULL
--	NULL
--	NULL
Myb	NULL
--	NULL
--	NULL
-	NULL
Mut	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Probe	NULL
:	NULL
NFAT	NULL
MYB	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Definition	NULL
of	NULL
the	NULL
CMAT	NULL
binding	NULL
site	NULL
by	NULL
EMSA	NULL
and	NULL
methylation	NULL
interference	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
analysis	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
unactivated	NULL
and	NULL
activated	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
CMAT	NULL
sequence	NULL
(	NULL
Myb	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
.	NULL

Labeled	NULL
CMAT	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
unactivated	NULL
(	NULL
-	NULL
)	NULL
and	NULL
activated	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cells	NULL
in	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
respectively	NULL
,	NULL
without	NULL
competitor	NULL
oligonucleotide	NULL
(	NULL
0	NULL
)	NULL
;	NULL
lane	NULL
3	NULL
's	NULL
content	NULL
is	NULL
the	NULL
same	NULL
as	NULL
that	NULL
of	NULL
lane	NULL
2	NULL
except	NULL
for	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
75-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
with	NULL
the	NULL
guanines	NULL
at	NULL
-778	NULL
and	NULL
-779	NULL
changed	NULL
to	NULL
thymidines	NULL
(	NULL
Mut	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
CMAT	NULL
oligonucleotide	NULL
was	NULL
labeled	NULL
in	NULL
lane	NULL
4	NULL
.	NULL

The	NULL
activated	NULL
and	NULL
constitutive	NULL
complexes	NULL
are	NULL
labeled	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
the	NULL
CMAT	NULL
and	NULL
constitutive	NULL
complexes	NULL
formed	NULL
with	NULL
activated	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extract	NULL
.	NULL

The	NULL
coding	NULL
and	NULL
noncoding	NULL
strands	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
protected	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
coding	NULL
strand	NULL
are	NULL
marked	NULL
with	NULL
filled	NULL
circles	NULL
.	NULL

There	NULL
are	NULL
no	NULL
protected	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
noncoding	NULL
strand	NULL
.	NULL

Lanes	NULL
1	NULL
contain	NULL
the	NULL
CMAT	NULL
complex	NULL
,	NULL
lanes	NULL
2	NULL
contain	NULL
free	NULL
oligonucleotide	NULL
,	NULL
and	NULL
lanes	NULL
3	NULL
contain	NULL
the	NULL
constitutive	NULL
complex	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
and	NULL
position	NULL
in	NULL
the	NULL
coding	NULL
strand	NULL
of	NULL
the	NULL
e-myb	NULL
promoter	NULL
where	NULL
methylation	NULL
interference	NULL
occurred	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
NFAT	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
and	NULL
c-myb	NULL
CMAT	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
site	NULL
probes	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
unactivated	NULL
(	NULL
-	NULL
)	NULL
and	NULL
activated	NULL
(	NULL
+	NULL
)	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cross-competition	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
75-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
c-myb	NULL
CMAT	NULL
site	NULL
(	NULL
M	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
the	NULL
NFAT	NULL
site	NULL
(	NULL
N	NULL
)	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

A	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
emyb	NULL
CMAT	NULL
site	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
or	NULL
the	NULL
NFAT	NULL
site	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
was	NULL
used	NULL
for	NULL
self-competition	NULL
.	NULL

The	NULL
activated	NULL
and	NULL
constitutive	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
myb	NULL
CMAT	NULL
probe	NULL
are	NULL
labeled	NULL
.	NULL

0	NULL
,	NULL
no	NULL
oligonucleotide	NULL
competitor	NULL
added	NULL
.	NULL

2390	NULL
PHAN	NULL
ET	NULL
AL	NULL
.	NULL

&	NULL
&	NULL
oar	NULL
C	NULL
&	NULL
wv	NULL
pro	NULL
pcm	NULL
mcg	NULL
-	NULL
Activated	NULL
u	NULL
-	NULL
Constitutive	NULL
«	NULL
Q	NULL
«	NULL
0	NULL
Ctl	NULL
e	NULL
ﬁg	NULL
ﬁt	NULL
$	NULL
foul	NULL
b4	NULL
U0	NULL
bue	NULL
Wth	NULL
bood	NULL
Shift	NULL
NFAT—	NULL
5	NULL
6	NULL
7	NULL
8	NULL
MYB	NULL
Probe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
NFAT	NULL
Probe	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
antibodies	NULL
on	NULL
the	NULL
EMSA	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
NFAT	NULL
and	NULL
myb	NULL
CMAT	NULL
probes	NULL
and	NULL
Jurkat	NULL
nuclear	NULL
extract	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
(	NULL
-	NULL
)	NULL
was	NULL
used	NULL
in	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
,	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
was	NULL
used	NULL
in	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
and	NULL
6	NULL
to	NULL
8	NULL
.	NULL

The	NULL
following	NULL
antibodies	NULL
were	NULL
added	NULL
:	NULL
preimmune	NULL
serum	NULL
(	NULL
Ctl	NULL
)	NULL
in	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
,	NULL
antibody	NULL
against	NULL
NFAT	NULL
,	NULL
in	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
,	NULL
and	NULL
antibody	NULL
against	NULL
NFAT	NULL
,	NULL
in	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
.	NULL

The	NULL
NFAT	NULL
complex	NULL
,	NULL
the	NULL
supershifted	NULL
NFAT	NULL
complex	NULL
,	NULL
and	NULL
the	NULL
activated	NULL
and	NULL
constitutive	NULL
myb	NULL
CMAT	NULL
complexes	NULL
are	NULL
labeled	NULL
.	NULL

mass	NULL
of	NULL
110	NULL
kDa	NULL
was	NULL
found	NULL
for	NULL
the	NULL
NFAT	NULL
protein	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
CMAT	NULL
protein	NULL
migrated	NULL
more	NULL
rapidly	NULL
;	NULL
its	NULL
estimated	NULL
molecular	NULL
mass	NULL
was	NULL
90	NULL
kDa	NULL
.	NULL

We	NULL
also	NULL
analyzed	NULL
the	NULL
constitutive	NULL
complex	NULL
and	NULL
found	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
60	NULL
kDa	NULL
for	NULL
this	NULL
complex	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
CMAT	NULL
complex	NULL
does	NULL
not	NULL
contain	NULL
the	NULL
same	NULL
proteins	NULL
as	NULL
the	NULL
NFAT	NULL
complex	NULL
does	NULL
.	NULL

Appearance	NULL
of	NULL
CMAT	NULL
binding	NULL
activity	NULL
over	NULL
time	NULL
.	NULL

To	NULL
determine	NULL
when	NULL
CMAT	NULL
binding	NULL
activity	NULL
first	NULL
appears	NULL
after	NULL
PMA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
at	NULL
various	NULL
times	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

An	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
these	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
CMAT	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
the	NULL
CMAT	NULL
complex	NULL
is	NULL
visible	NULL
at	NULL
1.5	NULL
h	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
CMAT	NULL
binding	NULL
activity	NULL
peaks	NULL
at	NULL
8	NULL
h	NULL
posttreatment	NULL
,	NULL
but	NULL
the	NULL
complex	NULL
is	NULL
still	NULL
visible	NULL
at	NULL
16	NULL
to	NULL
24	NULL
h.	NULL
The	NULL
same	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
NFAT	NULL
probe	NULL
.	NULL

Consistent	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
35	NULL
)	NULL
,	NULL
the	NULL
NFAT	NULL
complex	NULL
appeared	NULL
15	NULL
to	NULL
30	NULL
min	NULL
after	NULL
the	NULL
activation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
CMAT	NULL
complex	NULL
appeared	NULL
approximately	NULL
75	NULL
min	NULL
after	NULL
the	NULL
NFAT	NULL
complex	NULL
did	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
interleukin-2	NULL
gene	NULL
is	NULL
induced	NULL
earlier	NULL
than	NULL
the	NULL
c-myb	NULL
gene	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

Figure	NULL
5B	NULL
shows	NULL
the	NULL
time	NULL
course	NULL
of	NULL
induction	NULL
of	NULL
c-myh	NULL
mRNA	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
during	NULL
activation	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
the	NULL
10	NULL
2	NULL
s	NULL
kD	NULL
200	NULL
-	NULL
«	NULL
-	NULL
110	NULL
kDa	NULL
«	NULL
<	NULL
-	NULL
30	NULL
kD	NULL
97.4-	NULL
a	NULL
59.0-	NULL
<	NULL
-	NULL
60	NULL
kDa	NULL
46.0-	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Denaturing	NULL
SDS-polyacrylamide	NULL
gel	NULL
analysis	NULL
of	NULL
the	NULL
UV	NULL
cross-linked	NULL
EMSA	NULL
complexes	NULL
formed	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
NFAT	NULL
and	NULL
myb	NULL
CMAT	NULL
probes	NULL
.	NULL

Protein	NULL
from	NULL
the	NULL
NFAT	NULL
complex	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
1	NULL
,	NULL
protein	NULL
from	NULL
the	NULL
activated	NULL
myb	NULL
CMAT	NULL
complex	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
2	NULL
,	NULL
and	NULL
protein	NULL
from	NULL
the	NULL
constitutive	NULL
myb	NULL
complex	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
3	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
shown	NULL
.	NULL

After	NULL
correction	NULL
for	NULL
the	NULL
bound	NULL
oligonucleotide	NULL
,	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
the	NULL
CMAT	NULL
protein	NULL
is	NULL
90	NULL
kDa	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
Time	NULL
(	NULL
hr	NULL
)	NULL
:	NULL
0	NULL
0.25	NULL
0.5	NULL
1	NULL
1.5	NULL
2	NULL
25	NULL
3	NULL
10	NULL
16	NULL
-	NULL
Activated	NULL
“	NULL
Hung	NULL
-Constitutive	NULL
B	NULL
Hrs	NULL
:	NULL
0	NULL
3	NULL
5	NULL
10	NULL
15	NULL
24	NULL
c-myb	NULL
-i	NULL
»	NULL
.	NULL

“	NULL
.	NULL

GAPoH	NULL
-	NULL
»	NULL
Sa	NULL
aa	NULL
aa	NULL
a	NULL
on	NULL
Be	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Appearances	NULL
of	NULL
the	NULL
CMAT	NULL
EMSA	NULL
complex	NULL
and	NULL
endogenous	NULL
c-myh	NULL
mRNA	NULL
over	NULL
time	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Appearance	NULL
of	NULL
the	NULL
CMAT	NULL
complex	NULL
over	NULL
time	NULL
by	NULL
EMSA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

The	NULL
activated	NULL
and	NULL
constitutive	NULL
complexes	NULL
are	NULL
labeled	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
the	NULL
induction	NULL
of	NULL
e-myb	NULL
mRNA	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

GAPDH	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
.	NULL

level	NULL
of	NULL
c-myb	NULL
mRNA	NULL
is	NULL
seen	NULL
at	NULL
5	NULL
h	NULL
,	NULL
and	NULL
it	NULL
peaks	NULL
between	NULL
15	NULL
to	NULL
24	NULL
h.	NULL
The	NULL
time	NULL
course	NULL
of	NULL
induction	NULL
of	NULL
c-myb	NULL
mRNA	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
the	NULL
level	NULL
of	NULL
c-myb	NULL
mRNA	NULL
is	NULL
higher	NULL
in	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
than	NULL
in	NULL
resting	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

New	NULL
protein	NULL
synthesis	NULL
is	NULL
required	NULL
for	NULL
the	NULL
appearance	NULL
of	NULL
CMAT	NULL
binding	NULL
activity	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
requirements	NULL
for	NULL
CMAT	NULL
binding	NULL
activity	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
using	NULL
aniso-mycin	NULL
.	NULL

Anisomycin	NULL
inhibits	NULL
ribosomal	NULL
subunit	NULL
association	NULL
and	NULL
blocks	NULL
98	NULL
%	NULL
of	NULL
protein	NULL
synthesis	NULL
in	NULL
Jurkat	NULL
cells	NULL
at	NULL
100	NULL
wM	NULL
in	NULL
5	NULL
min	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
anisomycin	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
8	NULL
h.	NULL
An	NULL
EMSA	NULL
with	NULL
this	NULL
nuclear	NULL
extract	NULL
demonstrated	NULL
that	NULL
CMAT	NULL
binding	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
approximately	NULL
98	NULL
%	NULL
,	NULL
but	NULL
there	NULL
was	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
constitutive	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
and	NULL
rapamycin	NULL
on	NULL
CMAT	NULL
binding	NULL
activity	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
immunosuppressive	NULL
drugs	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
CMAT	NULL
binding	NULL
activity	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
several	NULL
different	NULL
concentrations	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
rapamycin	NULL
.	NULL

At	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
ng	NULL
of	NULL
cyclosporin	NULL
A	NULL
per	NULL
ml	NULL
,	NULL
the	NULL
CMAT	NULL
complex	NULL
was	NULL
not	NULL
visible	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
constitutive	NULL
complex	NULL
.	NULL

Rapamycin	NULL
at	NULL
concentrations	NULL
above	NULL
1	NULL
ng/ml	NULL
prevented	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
CMAT	NULL
complex	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
c-myb	NULL
promoter	NULL
activity	NULL
with	NULL
activation	NULL
was	NULL
also	NULL
abolished	NULL
by	NULL
cyclosporin	NULL
A	NULL
at	NULL
10	NULL
ng/ml	NULL
and	NULL
by	NULL
rapamycin	NULL
at	NULL
5	NULL
ng/ml	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
(	NULL
immunoblot	NULL
)	NULL
analysis	NULL
of	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
confirmed	NULL
that	NULL
no	NULL
induction	NULL
of	NULL
c-myb	NULL
expression	NULL
occurred	NULL
with	NULL
treatment	NULL
with	NULL
anisomycin	NULL
,	NULL
cyclosporin	NULL
A	NULL
,	NULL
or	NULL
rapamycin	NULL
at	NULL
these	NULL
concentrations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
Anisomycin	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
-	NULL
-	NULL
10	NULL
100	NULL
Activated	NULL
:	NULL
-_	NULL
+_	NULL
+	NULL
_+	NULL
--	NULL
Activated	NULL
-	NULL
Constitutive	NULL
1	NULL
20	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Effects	NULL
of	NULL
inhibition	NULL
of	NULL
protein	NULL
synthesis	NULL
on	NULL
CMAT	NULL
complex	NULL
binding	NULL
activity	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
or	NULL
100	NULL
wM	NULL
anisomycin	NULL
for	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
8	NULL
h	NULL
and	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
c-myb	NULL
CMAT	NULL
probe	NULL
.	NULL

An	NULL
in	NULL
vivo	NULL
footprint	NULL
is	NULL
located	NULL
over	NULL
the	NULL
CMAT	NULL
site	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
CMAT	NULL
site	NULL
was	NULL
occupied	NULL
in	NULL
vivo	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
by	NULL
ligation-mediated	NULL
PCR	NULL
was	NULL
used	NULL
to	NULL
examine	NULL
the	NULL
region	NULL
around	NULL
the	NULL
CMAT	NULL
site	NULL
in	NULL
both	NULL
unactivated	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
there	NULL
was	NULL
no	NULL
protection	NULL
of	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
CMAT	NULL
site	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
Myb	NULL
I	NULL
and	NULL
II	NULL
sites	NULL
were	NULL
protected	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
these	NULL
sites	NULL
function	NULL
as	NULL
negative	NULL
regulatory	NULL
elements	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
Myb	NULL
I	NULL
and	NULL
II	NULL
sites	NULL
were	NULL
not	NULL
protected	NULL
,	NULL
but	NULL
the	NULL
CMAT	NULL
site	NULL
was	NULL
protected	NULL
.	NULL

The	NULL
three	NULL
guanine	NULL
residues	NULL
required	NULL
for	NULL
binding	NULL
in	NULL
vitro	NULL
were	NULL
protected	NULL
in	NULL
vivo	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
results	NULL
from	NULL
EMSA	NULL
that	NULL
demonstrated	NULL
that	NULL
the	NULL
CMAT	NULL
binding	NULL
complex	NULL
was	NULL
present	NULL
only	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
did	NULL
not	NULL
find	NULL
any	NULL
evidence	NULL
for	NULL
in	NULL
vivo	NULL
binding	NULL
of	NULL
the	NULL
constitutively	NULL
expressed	NULL
60-kDa	NULL
protein	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
although	NULL
from	NULL
our	NULL
in	NULL
vitro	NULL
binding	NULL
studies	NULL
,	NULL
we	NULL
know	NULL
that	NULL
methylation	NULL
protection	NULL
is	NULL
not	NULL
the	NULL
best	NULL
technique	NULL
to	NULL
assess	NULL
binding	NULL
of	NULL
the	NULL
constitutive	NULL
complex	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
cyclosporin	NULL
A	NULL
prior	NULL
to	NULL
activation	NULL
resulted	NULL
in	NULL
no	NULL
footprint	NULL
over	NULL
the	NULL
CMAT	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
lane	NULL
C	NULL
)	NULL
;	NULL
the	NULL
footprint	NULL
results	NULL
were	NULL
very	NULL
similar	NULL
to	NULL
those	NULL
obtained	NULL
with	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
support	NULL
the	NULL
contention	NULL
that	NULL
the	NULL
in	NULL
vivo	NULL
footprint	NULL
is	NULL
due	NULL
to	NULL
the	NULL
CMAT	NULL
protein	NULL
and	NULL
not	NULL
the	NULL
constitutive	NULL
protein	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
has	NULL
been	NULL
performed	NULL
with	NULL
both	NULL
Jurkat	NULL
cells	NULL
and	NULL
primary	NULL
T	NULL
cells	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

The	NULL
footprints	NULL
from	NULL
primary	NULL
T	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

DISCUSSION	NULL
The	NULL
e-myb	NULL
gene	NULL
product	NULL
is	NULL
required	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
for	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
determine	NULL
the	NULL
mechanism	NULL
of	NULL
regulation	NULL
of	NULL
the	NULL
c-myb	NULL
gene	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
experiments	NULL
into	NULL
Jurkat	NULL
cells	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
region	NULL
located	NULL
between	NULL
positions	NULL
-784	NULL
and	NULL
-758	NULL
upstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
that	NULL
mediated	NULL
a	NULL
9.2-fold	NULL
increase	NULL
in	NULL
the	NULL
c-myb	NULL
promoter	NULL
activity	NULL
level	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
identify	NULL
two	NULL
potential	NULL
CMAT	NULL
sites	NULL
with	NULL
conserved	NULL
contact	NULL
bases	NULL
in	NULL
the	NULL
murine	NULL
e-myb	NULL
promoter	NULL
.	NULL

One	NULL
is	NULL
located	NULL
640	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
near	NULL
two	NULL
potential	NULL
Myb	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
the	NULL
other	NULL
is	NULL
570	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
.	NULL

In	NULL
the	NULL
chicken	NULL
c-myb	NULL
promoter	NULL
,	NULL
there	NULL
is	NULL
a	NULL
potential	NULL
CMAT	NULL
site	NULL
1,200	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
ATG	NULL
codon	NULL
.	NULL

Although	NULL
c-Myb	NULL
is	NULL
induced	NULL
in	NULL
murine	NULL
and	NULL
chicken	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
not	NULL
investigated	NULL
whether	NULL
these	NULL
potential	NULL
CMAT	NULL
sites	NULL
play	NULL
any	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
.	NULL

EMSA	NULL
analysis	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
demonstrated	NULL
that	NULL
a	NULL
new	NULL
protein	NULL
complex	NULL
bound	NULL
to	NULL
the	NULL
CMAT	NULL
INDUCIBLE	NULL
REGULATOR	NULL
OF	NULL
cmyb	NULL
EXPRESSION	NULL
2391	NULL
site	NULL
.	NULL

A	NULL
more	NULL
rapidly	NULL
migrating	NULL
constitutive	NULL
complex	NULL
was	NULL
formed	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
both	NULL
unactivated	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
a	NULL
potential	NULL
Ets	NULL
site	NULL
in	NULL
this	NULL
region	NULL
,	NULL
we	NULL
have	NULL
no	NULL
evidence	NULL
from	NULL
antibody	NULL
studies	NULL
that	NULL
either	NULL
of	NULL
these	NULL
proteins	NULL
is	NULL
an	NULL
Ets	NULL
family	NULL
member	NULL
.	NULL

Further	NULL
confirmation	NULL
of	NULL
the	NULL
function	NULL
of	NULL
the	NULL
CMAT	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
was	NULL
obtained	NULL
by	NULL
in	NULL
vivo	NULL
footprint	NULL
analysis	NULL
.	NULL

The	NULL
CMAT	NULL
site	NULL
was	NULL
occupied	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

Resting	NULL
T	NULL
cells	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
c-Myb	NULL
,	NULL
and	NULL
we	NULL
did	NULL
observe	NULL
that	NULL
the	NULL
Myb	NULL
I	NULL
and	NULL
II	NULL
sites	NULL
were	NULL
occupied	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
these	NULL
sites	NULL
function	NULL
as	NULL
negative	NULL
regulatory	NULL
regions	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Although	NULL
a	NULL
constitutively	NULL
expressed	NULL
binding	NULL
activity	NULL
is	NULL
observed	NULL
in	NULL
EMSA	NULL
,	NULL
we	NULL
could	NULL
find	NULL
no	NULL
evidence	NULL
for	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
by	NULL
methylation	NULL
protection	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
in	NULL
vivo	NULL
footprint	NULL
observed	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
represents	NULL
binding	NULL
of	NULL
the	NULL
constitutively	NULL
expressed	NULL
protein	NULL
,	NULL
we	NULL
believe	NULL
that	NULL
it	NULL
is	NULL
the	NULL
CMAT	NULL
protein	NULL
because	NULL
its	NULL
appearance	NULL
correlates	NULL
with	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
CMAT	NULL
EMSA	NULL
complex	NULL
and	NULL
the	NULL
same	NULL
three	NULL
guanine	NULL
residues	NULL
are	NULL
required	NULL
for	NULL
binding	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
no	NULL
footprint	NULL
is	NULL
visible	NULL
over	NULL
the	NULL
CMAT	NULL
site	NULL
if	NULL
the	NULL
T	NULL
cells	NULL
are	NULL
A	NULL
Cyclosporin	NULL
A	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

Rapamycin	NULL
(	NULL
ng/ml	NULL
)	NULL
-	NULL
-	NULL
10100	NULL
500	NULL
-o	NULL
-	NULL
O4	NULL
10	NULL
5	NULL
10	NULL
Activated	NULL
:	NULL
+	NULL
-	NULL
+	NULL
+	NULL
+	NULL
to	NULL
t	NULL
oto	NULL
4	NULL
o	NULL
grou	NULL
p	NULL
e	NULL
e	NULL
move	NULL
gromy	NULL
my	NULL
gong	NULL
mms	NULL
--	NULL
Qu	NULL
-	NULL
NOR	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
act	NULL
.	NULL

f	NULL
@	NULL
esa	NULL
Wrap	NULL
100	NULL
p	NULL
&	NULL
co	NULL
O	NULL
O	NULL
O	NULL
Luciferase	NULL
Activity	NULL
Io	NULL
O	NULL
0	NULL
-784	NULL
-758	NULL
Mut	NULL
-784	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
immunosuppressants	NULL
cyclosporin	NULL
A	NULL
and	NULL
rapamycin	NULL
on	NULL
the	NULL
CMAT	NULL
binding	NULL
complex	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
,	NULL
100	NULL
,	NULL
or	NULL
500	NULL
ng	NULL
of	NULL
cyclosporin	NULL
A	NULL
per	NULL
ml	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
or	NULL
with	NULL
0.1	NULL
,	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
rapamycin	NULL
per	NULL
ml	NULL
(	NULL
lanes	NULL
8	NULL
to	NULL
11	NULL
)	NULL
for	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
8	NULL
h	NULL
and	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
c-myh	NULL
CMAT	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transient	NULL
transfection	NULL
analysis	NULL
of	NULL
the	NULL
c-myb	NULL
promoter	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cyclosporin	NULL
A	NULL
or	NULL
rapamycin	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
csa	NULL
)	NULL
at	NULL
100	NULL
ng/ml	NULL
or	NULL
rapamycin	NULL
(	NULL
rap	NULL
)	NULL
at	NULL
5	NULL
ng/ml	NULL
was	NULL
added	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

unact	NULL
.	NULL

,	NULL
unactivated	NULL
;	NULL
act	NULL
.	NULL

,	NULL
activated	NULL
.	NULL

2392	NULL
PHAN	NULL
ET	NULL
AL	NULL
.	NULL

Resting	NULL
T	NULL
cells	NULL
Activated	NULL
T	NULL
cells	NULL
V	NULL
N	NULL
-851	NULL
N	NULL
v	NULL
C	NULL
-851	NULL
A	NULL
~~~	NULL
Myb	NULL
IL-	NULL
as	NULL
as	NULL
as	NULL
A	NULL
LE	NULL
]	NULL
®	NULL
G	NULL
m	NULL
«	NULL
a	NULL
T	NULL
T	NULL
Myb	NULL
II	NULL
-	NULL
«	NULL
»	NULL
«	NULL
»	NULL
A__	NULL
--	NULL
--	NULL
A\	NULL
wi	NULL
--	NULL
--	NULL
Myb	NULL
I	NULL
-	NULL
«	NULL
»	NULL
«	NULL
»	NULL
o	NULL
aeg	NULL
/	NULL
:	NULL
T	NULL
e	NULL
g	NULL
}	NULL
T	NULL
A	NULL
T	NULL
Go	NULL
A	NULL
__	NULL
A	NULL
___	NULL
omar-	NULL
WW	NULL
®	NULL
A	NULL
a	NULL
as	NULL
\ge	NULL
-mm	NULL
tm	NULL
C®	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

In	NULL
vivo	NULL
footprint	NULL
analysis	NULL
by	NULL
ligation-mediated	NULL
PCR	NULL
of	NULL
the	NULL
c-myh	NULL
CMAT	NULL
and	NULL
Myb	NULL
sites	NULL
in	NULL
resting	NULL
and	NULL
activated	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
coding	NULL
strand	NULL
is	NULL
illustrated	NULL
;	NULL
there	NULL
are	NULL
no	NULL
guanine	NULL
residues	NULL
in	NULL
the	NULL
noncoding	NULL
strand	NULL
in	NULL
this	NULL
region	NULL
.	NULL

The	NULL
nucleotide	NULL
numbers	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

N	NULL
denotes	NULL
in	NULL
vitro-methylated	NULL
DNA	NULL
,	NULL
V	NULL
denotes	NULL
in	NULL
vivo-methylated	NULL
DNA	NULL
,	NULL
and	NULL
C	NULL
denotes	NULL
treatment	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
cyclosporin	NULL
A	NULL
per	NULL
ml	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

The	NULL
protected	NULL
guanines	NULL
are	NULL
marked	NULL
by	NULL
filled	NULL
circles	NULL
.	NULL

Protection	NULL
of	NULL
guanine	NULL
is	NULL
64	NULL
%	NULL
at	NULL
position	NULL
-798	NULL
(	NULL
the	NULL
Myb	NULL
I	NULL
site	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
58	NULL
%	NULL
at	NULL
position	NULL
-812	NULL
(	NULL
the	NULL
Myb	NULL
II	NULL
site	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
68	NULL
%	NULL
at	NULL
positions	NULL
-779	NULL
and	NULL
-778	NULL
,	NULL
82	NULL
%	NULL
at	NULL
position	NULL
-782	NULL
(	NULL
the	NULL
CMAT	NULL
site	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
69	NULL
%	NULL
at	NULL
position	NULL
-798	NULL
(	NULL
the	NULL
Myb	NULL
I	NULL
site	NULL
in	NULL
cyclosporin-treated	NULL
cells	NULL
)	NULL
,	NULL
and	NULL
61	NULL
%	NULL
at	NULL
position	NULL
-812	NULL
(	NULL
the	NULL
Myb	NULL
II	NULL
site	NULL
in	NULL
cyclosporin-treated	NULL
cells	NULL
)	NULL
.	NULL

treated	NULL
with	NULL
cyclosporin	NULL
A	NULL
prior	NULL
to	NULL
activation	NULL
.	NULL

The	NULL
protected	NULL
guanines	NULL
at	NULL
-779	NULL
and	NULL
-778	NULL
are	NULL
required	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
CMAT	NULL
complex	NULL
and	NULL
for	NULL
transcriptional	NULL
activity	NULL
.	NULL

Although	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
NFAT	NULL
and	NULL
CMAT	NULL
show	NULL
some	NULL
sequence	NULL
homology	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
CMAT	NULL
protein	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
NFAT	NULL
protein	NULL
.	NULL

There	NULL
is	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
protected	NULL
guanines	NULL
(	NULL
underlined	NULL
)	NULL
in	NULL
each	NULL
of	NULL
the	NULL
binding	NULL
sites	NULL
:	NULL
CMAT	NULL
,	NULL
GAAGGAAAA	NULL
;	NULL
and	NULL
NFAT	NULL
,	NULL
AGAGGAAAA	NULL
.	NULL

Antibodies	NULL
against	NULL
either	NULL
NFAT	NULL
,	NULL
or	NULL
NFAT	NULL
,	NULL
did	NULL
not	NULL
react	NULL
with	NULL
the	NULL
CMAT	NULL
complex	NULL
.	NULL

UV	NULL
cross-link	NULL
analysis	NULL
demonstrated	NULL
that	NULL
the	NULL
CMAT	NULL
protein	NULL
migrated	NULL
more	NULL
rapidly	NULL
than	NULL
the	NULL
NFAT	NULL
protein	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
during	NULL
T-cell	NULL
activation	NULL
the	NULL
CMAT	NULL
binding	NULL
complex	NULL
was	NULL
induced	NULL
slightly	NULL
later	NULL
than	NULL
the	NULL
NFAT	NULL
complex	NULL
was	NULL
.	NULL

New	NULL
protein	NULL
synthesis	NULL
was	NULL
required	NULL
for	NULL
the	NULL
appearance	NULL
of	NULL
CMAT	NULL
binding	NULL
activity	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
no	NULL
CMAT	NULL
complex	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
anisomycin	NULL
prior	NULL
to	NULL
activation	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
with	NULL
cyclosporin	NULL
A	NULL
prior	NULL
to	NULL
activation	NULL
prevented	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
CMAT	NULL
complex	NULL
in	NULL
EMSA	NULL
and	NULL
the	NULL
in	NULL
vivo	NULL
footprint	NULL
over	NULL
this	NULL
site	NULL
.	NULL

Cyclosporin	NULL
treatment	NULL
also	NULL
abolished	NULL
the	NULL
induction	NULL
of	NULL
c-myb	NULL
promoter	NULL
activity	NULL
.	NULL

Treatment	NULL
with	NULL
rapamycin	NULL
had	NULL
a	NULL
similar	NULL
effect	NULL
.	NULL

Thus	NULL
,	NULL
inhibition	NULL
of	NULL
either	NULL
of	NULL
two	NULL
different	NULL
pathways	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
can	NULL
interfere	NULL
with	NULL
c-myb	NULL
expression	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
reported	NULL
for	NULL
another	NULL
nuclear	NULL
oncoprotein	NULL
,	NULL
c-jun	NULL
(	NULL
34	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
molecular	NULL
mass	NULL
and	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
CMAT	NULL
protein	NULL
,	NULL
we	NULL
believe	NULL
that	NULL
it	NULL
represents	NULL
a	NULL
novel	NULL
inducible	NULL
transcription	NULL
factor	NULL
.	NULL

Because	NULL
activated	NULL
T	NULL
cells	NULL
require	NULL
c-Myb	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
identification	NULL
of	NULL
the	NULL
factors	NULL
that	NULL
induce	NULL
c-Myb	NULL
expression	NULL
is	NULL
essential	NULL
for	NULL
an	NULL
understanding	NULL
of	NULL
the	NULL
events	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
CMAT	NULL
protein	NULL
appears	NULL
to	NULL
be	NULL
another	NULL
component	NULL
of	NULL
the	NULL
T-cell	NULL
activation	NULL
cascade	NULL
.	NULL

Further	NULL
characterization	NULL
of	NULL
this	NULL
novel	NULL
inducible	NULL
transcription	NULL
factor	NULL
and	NULL
a	NULL
determination	NULL
of	NULL
the	NULL
role	NULL
it	NULL
plays	NULL
in	NULL
T-cell	NULL
activation	NULL
are	NULL
under	NULL
way	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Department	NULL
of	NULL
Veterans	NULL
Affairs	NULL
and	NULL
by	NULL
NIH	NULL
grant	NULL
CA56764	NULL
.	NULL

S.-C.P	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
PHS	NULL
grant	NULL
NRSA	NULL
F32CA68728	NULL
awarded	NULL
by	NULL
the	NULL
NCI	NULL
,	NULL
Department	NULL
of	NULL
HHS	NULL
.	NULL

We	NULL
gratefully	NULL
acknowledge	NULL
Jerry	NULL
Crabtree	NULL
,	NULL
Stefan	NULL
Ho	NULL
,	NULL
and	NULL
Luika	NULL
Timmerman	NULL
for	NULL
providing	NULL
the	NULL
NFAT	NULL
,	NULL
and	NULL
NFAT	NULL
,	NULL
antibodies	NULL
and	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Arcinas	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Boxer	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
c-myc	NULL
promoter	NULL
during	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

Oncogene	NULL
9:2699-2706	NULL
.	NULL

2	NULL
.	NULL

Arcinas	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
C.	NULL
Sizer	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Boxer	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
c-myc	NULL
expression	NULL
by	NULL
c-Abl	NULL
is	NULL
independent	NULL
of	NULL
both	NULL
the	NULL
DNA	NULL
binding	NULL
function	NULL
of	NULL
c-Abl	NULL
and	NULL
the	NULL
c-myc	NULL
EP	NULL
site	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:21919-21924	NULL
.	NULL

3	NULL
.	NULL

Blackman	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Tigges	NULL
,	NULL
M.	NULL
E.	NULL
Minie	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Koshland	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
model	NULL
system	NULL
for	NULL
peptide	NULL
hormone	NULL
action	NULL
in	NULL
differentiation	NULL
:	NULL
interleukin	NULL
2	NULL
induces	NULL
a	NULL
B	NULL
lymphoma	NULL
to	NULL
transcribe	NULL
the	NULL
J	NULL
chain	NULL
gene	NULL
.	NULL

Cell	NULL
47:609-617	NULL
.	NULL

4	NULL
.	NULL

Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
M.	NULL
A.	NULL
Lampert	NULL
,	NULL
J.	NULL
S.	NULL
Lipsick	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Baluda	NULL
.	NULL

1984	NULL
.	NULL

Avian	NULL
myeloblastosis	NULL
virus	NULL
and	NULL
E26	NULL
virus	NULL
products	NULL
are	NULL
nuclear	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:4265-4269	NULL
.	NULL

5	NULL
.	NULL

Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
J.	NULL
S.	NULL
Lipsick	NULL
,	NULL
E.	NULL
P.	NULL
Reddy	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Baluda	NULL
.	NULL

1983	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
leukemogenic	NULL
protein	NULL
of	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
and	NULL
its	NULL
normal	NULL
cellular	NULL
homologue	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80:2834-2838	NULL
.	NULL

6	NULL
.	NULL

Chodosh	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

1988	NULL
.	NULL

UV	NULL
crosslinking	NULL
of	NULL
proteins	NULL
to	NULL
nucleic	NULL
acids	NULL
,	NULL
p.	NULL
12.5.1-12.5.6	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
.	NULL

7	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1987	NULL
.	NULL

Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162:156-159	NULL
.	NULL

8	NULL
.	NULL

Churilla	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
T.	NULL
J.	NULL
Braciale	NULL
,	NULL
and	NULL
V.	NULL
L.	NULL
Braciale	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
:	NULL
interleukin	NULL
2-mediated	NULL
induction	NULL
of	NULL
c-myb	NULL
gene	NULL
expression	NULL
is	NULL
dependent	NULL
on	NULL
T	NULL
lymphocyte	NULL
activation	NULL
state	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

170:105-121	NULL
.	NULL

9	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.	NULL
P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belageje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

10	NULL
.	NULL

Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
B.	NULL
Corthesy	NULL
,	NULL
R.	NULL
J.	NULL
Bram	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
association	NULL
of	NULL
a	NULL
T-cell	NULL
transcription	NULL
factor	NULL
blocked	NULL
by	NULL
FK-506	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
352:803-807	NULL
.	NULL

11	NULL
.	NULL

Garrity	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
B.	NULL
Wold	NULL
.	NULL

1992	NULL
.	NULL

Effects	NULL
of	NULL
different	NULL
DNA	NULL
polymerases	NULL
in	NULL
ligation-mediated	NULL
PCR	NULL
:	NULL
enhanced	NULL
genomic	NULL
sequencing	NULL
and	NULL
in	NULL
vivo	NULL
footprint-ing	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1021-1025	NULL
.	NULL

12	NULL
.	NULL

Gewirtz	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Anfossi	NULL
,	NULL
D.	NULL
Venturelli	NULL
,	NULL
S.	NULL
Valpreda	NULL
,	NULL
R.	NULL
Sims	NULL
,	NULL
and	NULL
B.	NULL
Calabretta	NULL
.	NULL

1989	NULL
.	NULL

G1/S	NULL
transition	NULL
in	NULL
normal	NULL
human	NULL
T-lymphocytes	NULL
requires	NULL
the	NULL
nuclear	NULL
protein	NULL
encoded	NULL
by	NULL
c-myb	NULL
.	NULL

Science	NULL
245:180-183	NULL
.	NULL

13	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Smithe	NULL
.	NULL

1977	NULL
.	NULL

Long	NULL
term	NULL
culture	NULL
of	NULL
tumour-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
268:154-156	NULL
.	NULL

14	NULL
.	NULL

Guerra	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
A.	NULL
Withers	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Boxer	NULL
.	NULL

1995	NULL
.	NULL

Myb	NULL
binding	NULL
sites	NULL
mediate	NULL
negative	NULL
regulation	NULL
of	NULL
c-myb	NULL
expression	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
86:1873-1880	NULL
.	NULL

15	NULL
.	NULL

Higuchi	NULL
,	NULL
R.	NULL
1990	NULL
.	NULL

Recombinant	NULL
PCR	NULL
,	NULL
p.	NULL
177-183.	NULL
in	NULL
M.	NULL
Innis	NULL
,	NULL
D.	NULL
Gelfand	NULL
,	NULL
J.	NULL
Sninsky	NULL
,	NULL
and	NULL
T.	NULL
White	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
PCR	NULL
protocols	NULL
:	NULL
a	NULL
guide	NULL
to	NULL
methods	NULL
and	NULL
appli-cations	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
Inc.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
16	NULL
.	NULL

Jacobs	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
K.	NULL
M.	NULL
Gorse	NULL
,	NULL
and	NULL
E.	NULL
H.	NULL
Westin	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
second	NULL
promoter	NULL
in	NULL
the	NULL
human	NULL
c-myb	NULL
proto-oncogene	NULL
.	NULL

Oncogene	NULL
9:227-235	NULL
.	NULL

17	NULL
.	NULL

Kaczmarek	NULL
,	NULL
L.	NULL
,	NULL
B.	NULL
Calabretta	NULL
,	NULL
and	NULL
R.	NULL
Baserga	NULL
.	NULL

1985	NULL
.	NULL

Effect	NULL
of	NULL
interleukin-2	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
genes	NULL
in	NULL
human	NULL
T-lymphocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

133:410-416	NULL
.	NULL

18	NULL
.	NULL

Klempnauer	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
G.	NULL
Ramsey	NULL
,	NULL
J.	NULL
M.	NULL
Bishop	NULL
,	NULL
M.	NULL
G.	NULL
Moscovici	NULL
,	NULL
C.	NULL
Moscovici	NULL
,	NULL
J.	NULL
P.	NULL
McGrath	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Levinson	NULL
.	NULL

1983	NULL
.	NULL

The	NULL
product	NULL
of	NULL
the	NULL
retroviral	NULL
transforming	NULL
gene	NULL
v-myb	NULL
is	NULL
a	NULL
truncated	NULL
version	NULL
of	NULL
the	NULL
protein	NULL
encoded	NULL
by	NULL
the	NULL
cellular	NULL
oncogene	NULL
c-myb	NULL
.	NULL

Cell	NULL
33:345-355	NULL
.	NULL

19	NULL
.	NULL

Klempnauer	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Sippel	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
highly	NULL
conserved	NULL
amino-terminal	NULL
region	NULL
of	NULL
the	NULL
protein	NULL
encoded	NULL
by	NULL
the	NULL
v-myb	NULL
oncogene	NULL
functions	NULL
as	NULL
a	NULL
DNA-binding	NULL
domain	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:2719-2725	NULL
.	NULL

20	NULL
.	NULL

Majello	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
C.	NULL
Kenyon	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
c-myb	NULL
pro-tooncogene	NULL
:	NULL
nucleotide	NULL
sequence	NULL
of	NULL
cDNA	NULL
and	NULL
organization	NULL
of	NULL
the	NULL
genomic	NULL
locus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:9636-9640	NULL
.	NULL

21	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1980	NULL
.	NULL

Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavages	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:499-560	NULL
.	NULL

22	NULL
.	NULL

McCann	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Sullivan	NULL
,	NULL
J.	NULL
Guerra	NULL
,	NULL
M.	NULL
Arcinas	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Boxer	NULL
.	NULL

1995	NULL
.	NULL

Repression	NULL
of	NULL
the	NULL
e-myb	NULL
gene	NULL
by	NULL
WT1	NULL
protein	NULL
in	NULL
T	NULL
and	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:23785-23789	NULL
.	NULL

23	NULL
.	NULL

Moelling	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Pfoff	NULL
,	NULL
H.	NULL
Beug	NULL
,	NULL
P.	NULL
Beimling	NULL
,	NULL
T.	NULL
Bunte	NULL
,	NULL
H.	NULL
E.	NULL
Schaller	NULL
,	NULL
and	NULL
T.	NULL
Graf	NULL
.	NULL

1985	NULL
.	NULL

DNA	NULL
binding	NULL
activity	NULL
is	NULL
associated	NULL
with	NULL
purified	NULL
Myb	NULL
proteins	NULL
from	NULL
AMV	NULL
and	NULL
E26	NULL
viruses	NULL
and	NULL
is	NULL
temperature-sensitive	NULL
for	NULL
E26	NULL
ts	NULL
mutants	NULL
.	NULL

Cell	NULL
40:983-990	NULL
.	NULL

24	NULL
.	NULL

Mountz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Subler	NULL
.	NULL

1993	NULL
.	NULL

Regulation	NULL
of	NULL
c-myb	NULL
oncogene	NULL
expression	NULL
in	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33.	NULL
immature	NULL
and	NULL
mature	NULL
murine	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Immunol	NULL
.	NULL

30:787-795	NULL
.	NULL

Mueller	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
and	NULL
B.	NULL
Wold	NULL
.	NULL

1989	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
a	NULL
muscle	NULL
specific	NULL
enhancer	NULL
by	NULL
ligation	NULL
mediated	NULL
PCR	NULL
.	NULL

Science	NULL
246:780-786	NULL
.	NULL

Nicolaides	NULL
,	NULL
N.	NULL
,	NULL
L	NULL
Correa	NULL
,	NULL
C.	NULL
Casadevalli	NULL
,	NULL
S.	NULL
Travali	NULL
,	NULL
K.	NULL
Soprano	NULL
,	NULL
and	NULL
B.	NULL
Calabretta	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Jun	NULL
family	NULL
members	NULL
c-Jun	NULL
and	NULL
JunD	NULL
transactivate	NULL
the	NULL
human	NULL
c-myb	NULL
promoter	NULL
via	NULL
an	NULL
AP-1	NULL
element	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:19665-19672	NULL
.	NULL

Nicolaides	NULL
,	NULL
N.	NULL
,	NULL
R.	NULL
Gualdi	NULL
,	NULL
C.	NULL
Casadevall	NULL
,	NULL
L.	NULL
Manzella	NULL
,	NULL
and	NULL
B.	NULL
Calabretta	NULL
.	NULL

1991	NULL
.	NULL

Positive	NULL
autoregulation	NULL
of	NULL
c-myb	NULL
expression	NULL
via	NULL
Myb	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
5°	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
human	NULL
c-myb	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:6166-6176	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
369:497-502	NULL
.	NULL

Northrup	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
components	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
complex	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:2917-2923	NULL
.	NULL

O'Garra	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Umland	NULL
,	NULL
T.	NULL
DeFrance	NULL
,	NULL
and	NULL
J.	NULL
Christiansen	NULL
.	NULL

1988	NULL
.	NULL
'	NULL

B-cell	NULL
factors	NULL
'	NULL
are	NULL
pleiotropic	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
9:45-54	NULL
.	NULL

Pauza	NULL
,	NULL
C.	NULL
D.	NULL
1987	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
T-lymphocyte	NULL
gene	NULL
expression	NULL
by	NULL
interleukin	NULL
2	NULL
:	NULL
immediate-response	NULL
genes	NULL
include	NULL
the	NULL
proto-oncogene	NULL
c-myb	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:342-348	NULL
.	NULL

Pfeifer	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
S.	NULL
D.	NULL
Steigerwald	NULL
,	NULL
P.	NULL
R.	NULL
Mueller	NULL
,	NULL
B.	NULL
Wold	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Riggs	NULL
.	NULL

1989	NULL
.	NULL

Genomic	NULL
sequencing	NULL
and	NULL
methylation	NULL
analysis	NULL
by	NULL
ligation	NULL
mediated	NULL
PCR	NULL
.	NULL

Science	NULL
246:810-813	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
J.	NULL
D.	NULL
Alpers	NULL
,	NULL
P.	NULL
C.	NULL
Nowell	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Hoover	NULL
.	NULL

1986	NULL
.	NULL

Sequential	NULL
INDUCIBLE	NULL
REGULATOR	NULL
OF	NULL
cmyb	NULL
EXPRESSION	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

2393	NULL
expression	NULL
of	NULL
protooncogenes	NULL
during	NULL
lectin-stimulated	NULL
mitogenesis	NULL
of	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:3982-3986	NULL
.	NULL

Shan	NULL
,	NULL
X.	NULL
,	NULL
H.	NULL
Luo	NULL
,	NULL
H.	NULL
Chen	NULL
,	NULL
P.	NULL
Daloze	NULL
,	NULL
G.	NULL
St-Louis	NULL
,	NULL
and	NULL
J.	NULL
Wu	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
rapamycin	NULL
on	NULL
c-jun	NULL
expression	NULL
in	NULL
human	NULL
lymphocytes	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

69:314-317	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Stern	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
K.	NULL
Smith	NULL
.	NULL

1986	NULL
.	NULL

Interleukin-2	NULL
induction	NULL
of	NULL
T-cell	NULL
G1	NULL
progression	NULL
and	NULL
c-myb	NULL
expression	NULL
.	NULL

Science	NULL
233:203-206	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
P.	NULL
B.	NULL
Challoner	NULL
,	NULL
P.	NULL
E.	NULL
Neiman	NULL
,	NULL
and	NULL
M.	NULL
Groudine	NULL
.	NULL

1986	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
e-myb	NULL
proto-oncogene	NULL
during	NULL
cellular	NULL
proliferation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
319:374-380	NULL
.	NULL

Torelli	NULL
,	NULL
G.	NULL
,	NULL
L.	NULL
Selleri	NULL
,	NULL
A.	NULL
Donelli	NULL
,	NULL
S.	NULL
Ferrari	NULL
,	NULL
G.	NULL
Emilia	NULL
,	NULL
D.	NULL
Venturelli	NULL
,	NULL
L.	NULL
Moretti	NULL
,	NULL
and	NULL
U.	NULL
Torelli	NULL
.	NULL

1985	NULL
.	NULL

Activation	NULL
of	NULL
c-myb	NULL
expression	NULL
by	NULL
phytohem-agglutinin	NULL
stimulation	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:12874-2877	NULL
.	NULL

Tso	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
X.-H.	NULL
Sun	NULL
,	NULL
T.-H.	NULL
Kao	NULL
,	NULL
K.	NULL
S.	NULL
Reece	NULL
,	NULL
and	NULL
R.	NULL
Wu	NULL
.	NULL

1985	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
rat	NULL
and	NULL
human	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
cDNAs	NULL
:	NULL
genomic	NULL
complexity	NULL
and	NULL
molecular	NULL
evolution	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

13:2485-2502	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
C.	NULL
Guidos	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Cell	NULL
type	NULL
specificity	NULL
and	NULL
activation	NULL
requirements	NULL
for	NULL
NFAT-1	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
)	NULL
transcriptional	NULL
activity	NULL
determined	NULL
by	NULL
a	NULL
new	NULL
method	NULL
using	NULL
transgenic	NULL
mice	NULL
to	NULL
assay	NULL
transcriptional	NULL
activity	NULL
of	NULL
an	NULL
individual	NULL
nuclear	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:15788-15795	NULL
.	NULL

